A randomized double-blind treatment strategy study evaluating continuation or reduced-frequency dosing of certolizumab pegol versus withdrawal to maintain low disease activity in early RA patients

X. Mariette, P. Emery, C. Bingham, G. Burmester, V. Bykerk, D. E. Furst, D. Van Der Heijde, R. Van Vollenhoven, B. Vanlunen, C. Ecoffet, C. Cioffi, M. Weinblatt

Research output: Contribution to journalArticlepeer-review

Original languageEnglish (US)
Pages (from-to)A56-A57
JournalRevue du Rhumatisme (Edition Francaise)
Volume83
DOIs
StatePublished - Nov 1 2016

ASJC Scopus subject areas

  • Rheumatology

Cite this